Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Pokaži ostale verzije (1)

Bibliografski detalji
Glavni autori:	Vora, A, Goulden, N, Wade, R, Mitchell, C, Hancock, J, Hough, R, Rowntree, C, Richards, S
Format:	Journal article
Izdano:	2013

Slični predmeti

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
od: Vora, A, i dr.
Izdano: (2013)

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema
od: Vora, A, i dr.
Izdano: (2012)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
od: Vora, A, i dr.
Izdano: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
od: Vora, A, i dr.
Izdano: (2014)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
od: Vora, A, i dr.
Izdano: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
od: Vora, A, i dr.
Izdano: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
od: Vora, A, i dr.
Izdano: (2010)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
od: Patrick, K, i dr.
Izdano: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
od: Patrick, K, i dr.
Izdano: (2014)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
od: Vora, A, i dr.
Izdano: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
od: Vora, A, i dr.
Izdano: (2008)

Characteristics and outcome of children and young adults with Early T-Precursor (ETP) ALL treated on UKALL 2003
od: Patrick, K, i dr.
Izdano: (2013)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
od: Cutting, R, i dr.
Izdano: (2008)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
od: Cutting, R, i dr.
Izdano: (2009)

PROSPECTIVE EVALUATION OF QUALITY OF LIFE (QOL) IN CHILDREN TREATED IN UKALL 2003 FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): A COHORT STUDY
od: Eiser, C, i dr.
Izdano: (2012)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
od: Samarasinghe, S, i dr.
Izdano: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
od: Samarasinghe, S, i dr.
Izdano: (2013)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
od: O'Connor, D, i dr.
Izdano: (2014)

Prospective evaluation of quality of life in children treated in UKALL 2003 for Acute Lymphoblastic Leukaemia (ALL): A cohort study
od: Eiser, C, i dr.
Izdano: (2017)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
od: O'Connor, D, i dr.
Izdano: (2014)

Outcome of Thrombosis in UKALL 2003-Anticoagulation and Re-Exposure to Aspariginase Is Feasible and Safe.
od: Qureshi, A, i dr.
Izdano: (2008)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
od: Patrick, K, i dr.
Izdano: (2014)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
od: Patrick, K, i dr.
Izdano: (2014)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
od: Moorman, A, i dr.
Izdano: (2008)

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.
od: Jenkinson, S, i dr.
Izdano: (2013)

Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
od: Qureshi, A, i dr.
Izdano: (2010)

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
od: Vora, A, i dr.
Izdano: (2008)

Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)
od: Tomlins, J, i dr.
Izdano: (2012)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)
od: Moorman, A, i dr.
Izdano: (2007)

No association of HLA-A supertype with outcome in childhood acute lymphoblastic leukaemia: results of the UKALL XI trial.
od: Thompson, P, i dr.
Izdano: (2011)

Variables affecting kinetics of minimal residual disease clearance in children with lymphoblastic leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) protocols ALL97, ALL97/99 and ALL2003.
od: Vora, A, i dr.
Izdano: (2005)

Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial
od: Jenkinson, S, i dr.
Izdano: (2012)

Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials.
od: Chessells, J, i dr.
Izdano: (1995)

Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
od: Hann, I, i dr.
Izdano: (2000)

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
od: Moorman, A, i dr.
Izdano: (2013)

UKALL XI randomised trial stratified CNS treatments and prospective neuropsychological assessment in childhood acute lymphoblastic leukaemia (ALL).
od: Hill, F, i dr.
Izdano: (2000)

Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
od: Chessels, J, i dr.
Izdano: (1997)

Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.
od: Wheeler, K, i dr.
Izdano: (1996)

High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis.
od: Patel, B, i dr.
Izdano: (2008)

Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
od: Chessells, J, i dr.
Izdano: (1997)